Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 51,300 shares, an increase of 57.8% from the February 13th total of 32,500 shares. Approximately 1.3% of the company's stock are short sold. Based on an average daily trading volume, of 66,900 shares, the short-interest ratio is presently 0.8 days.
Monopar Therapeutics Price Performance
MNPR traded up $4.73 during trading on Wednesday, reaching $39.10. 46,159 shares of the company's stock were exchanged, compared to its average volume of 359,032. Monopar Therapeutics has a 1 year low of $1.72 and a 1 year high of $54.30. The company's fifty day simple moving average is $36.16 and its 200-day simple moving average is $21.99. The stock has a market capitalization of $238.59 million, a P/E ratio of -19.85 and a beta of 1.18.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in MNPR. Janus Henderson Group PLC acquired a new stake in Monopar Therapeutics during the 4th quarter worth about $23,435,000. Adage Capital Partners GP L.L.C. purchased a new position in Monopar Therapeutics during the fourth quarter valued at approximately $13,182,000. RA Capital Management L.P. acquired a new position in Monopar Therapeutics in the fourth quarter valued at approximately $11,247,000. Point72 Asset Management L.P. purchased a new stake in Monopar Therapeutics in the 4th quarter worth approximately $3,694,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Monopar Therapeutics during the 4th quarter worth approximately $2,861,000. Hedge funds and other institutional investors own 1.83% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms recently commented on MNPR. Piper Sandler reissued an "overweight" rating and set a $76.00 target price on shares of Monopar Therapeutics in a research report on Wednesday. HC Wainwright increased their price objective on Monopar Therapeutics from $22.00 to $40.00 and gave the company a "buy" rating in a report on Wednesday, January 22nd.
Check Out Our Latest Stock Report on Monopar Therapeutics
Monopar Therapeutics Company Profile
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Featured Stories
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.